// App-Quantinova.ai

1210 : Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis

Researchers

Presenter

  • Namrata Singh

Principal Investigators

  • Alexander Peterson

  • Aaron Baraff

  • Ajay Gopal

  • Nicholas Smith

  • Jennifer Barton

  • Jeffrey Curtis

  • Noel Weiss

Medical Centers

  • University of Washington, Seattle, WA

  • VA Puget Sound, SEATTLE, WA

  • University of Washington, Seattle, WA

  • VA-Puget Sound/University of Washington, Seattle, WA

  • VA Portland Health Care System, Portland, OR

  • University of Alabama at Birmingham, Birmingham, AL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Rheumatoid arthritis

  • Lymphomas

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • Tocilizumab

  • leflunomide

  • Tasocitinib

  • Abatacept

  • Rituximab

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved